Background
Phase 3, multicenter, randomized, open-label trial (ECOG-ACRIN E1910, NCT02003222). Adults aged 30–70 with newly diagnosed BCR::ABL1-negative B-cell precursor ALL received standard induction then consolidation. Those achieving MRD-negative complete response (MRD <0.01% by 6-color flow cytometry) after induction/intensification were randomized; 224 were randomized of 488 enrolled who achieved MRD-negative CR. Published NEJM 2024.
Interventions and follow up
Arm A: Blinatumomab 28 µg/day continuous IV ×4 cycles (28 days on, 14 off) plus continuing consolidation chemotherapy (N=112)
Arm B: Standard consolidation chemotherapy alone (N=112)
Primary endpoint: Overall survival
Median follow-up: ~4.5 years
Arm B: Standard consolidation chemotherapy alone (N=112)
Primary endpoint: Overall survival
Median follow-up: ~4.5 years
Results
OS (primary): HR 0.41 (95% CI 0.23–0.73), P=.003 favoring blinatumomab + chemo
3-year OS: 85% (blinatumomab + chemo) vs 68% (chemo alone)
3-year RFS: 80% vs 66%
MRD conversion: ~30% of patients still MRD-positive at randomization became MRD-negative on blinatumomab
Subgroups: OS benefit consistent across age, sex, and cytogenetic subgroups
3-year OS: 85% (blinatumomab + chemo) vs 68% (chemo alone)
3-year RFS: 80% vs 66%
MRD conversion: ~30% of patients still MRD-positive at randomization became MRD-negative on blinatumomab
Subgroups: OS benefit consistent across age, sex, and cytogenetic subgroups
Adverse events
Neurologic (grade ≥3): 23% (blinatumomab) vs 5% (chemo alone) — chiefly encephalopathy, aphasia, tremor
Cytokine release syndrome: Low rate with blinatumomab
Infectious/fatal: Grade ≥3 infections similar between arms; treatment-related deaths 2% (blinatumomab) vs 0% (control); no unexpected blinatumomab toxicities
Cytokine release syndrome: Low rate with blinatumomab
Infectious/fatal: Grade ≥3 infections similar between arms; treatment-related deaths 2% (blinatumomab) vs 0% (control); no unexpected blinatumomab toxicities
Conclusions
Adding blinatumomab to consolidation chemotherapy in MRD-negative BCR::ABL1-negative adult B-ALL improved 3-year OS from 68% to 85% (HR 0.41, P=.003) — a 17 percentage-point absolute benefit. This is the first phase 3 OS benefit for blinatumomab in newly diagnosed ALL and the first to show benefit of immunotherapy consolidation even in MRD-negative patients.
Key Limitations
MRD assessment by 6-color flow cytometry may be less sensitive than PCR/NGS-based methods, so some MRD-negative patients may harbor molecular disease. MRD-positive patients were not randomized, so the trial cannot inform that subgroup. The PETHEMA-like consolidation backbone may not be universally adopted; cross-comparison with hyperCVAD/GRAALL backbones requires caution. Median age was ~51, leaving generalizability to patients >70 unknown. Long-term OS beyond ~4.5 years awaited.
Clinical Context
ECOG E1910 is practice-changing: blinatumomab during consolidation is now a standard of care for MRD-negative adult BCR::ABL1-negative B-ALL. The FDA expanded the blinatumomab label (June 2024) to include CD19-positive Ph-negative B-ALL in the consolidation phase based on this and supporting data. The trial demonstrates that immunotherapy consolidation deepens remission and improves survival even in patients already MRD-negative, reframing how MRD-negative status is managed.